Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide: current uses.

R J Powell1

  • 1Clinical Immunology Unit, University Hospital, Queen's Medical Centre, Nottingham, England.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML.

Leukemia·2015
Same author

A randomized controlled trial of postoperative analgesia following total knee replacement: transdermal Fentanyl patches versus patient controlled analgesia (PCA).

European journal of orthopaedic surgery & traumatology : orthopedie traumatologie·2015
Same author

BSACI guideline for the management of chronic urticaria and angioedema.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015
Same author

Accuracy of the Lightman(®) pulse oximeter tester.

Anaesthesia·2012
Same author

Surgical smoke - a health hazard in the operating theatre: a study to quantify exposure and a survey of the use of smoke extractor systems in UK plastic surgery units.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2012
Same author

NOD2 polymorphisms in clinical phenotypes of common variable immunodeficiency disorders.

Clinical and experimental immunology·2010
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Thalidomide offers therapeutic benefits by inhibiting tumor necrosis factor-alpha and altering integrins. However, its use is limited by teratogenicity and neuropathy, necessitating strict safety guidelines for patients.

Area of Science:

  • Immunology
  • Pharmacology
  • Neurology

Background:

  • Thalidomide selectively inhibits tumor necrosis factor-alpha production by monocytes.
  • It also alters the cellular surface expression of integrins, contributing to its therapeutic effects.
  • Despite significant drawbacks like teratogenicity and neuropathy, thalidomide has a niche role in treating refractory conditions.

Purpose of the Study:

  • To review the therapeutic effects and drawbacks of thalidomide.
  • To highlight its current clinical applications, including erythema nodosum leprosum, graft versus host disease, and ulcers associated with HIV and Behçet's disease.
  • To emphasize the importance of safety guidelines and monitoring due to tolerability issues.

Main Methods:

  • Review of existing literature on thalidomide's mechanism of action, therapeutic uses, and adverse events.

Related Experiment Videos

  • Analysis of clinical trial data, particularly concerning rheumatoid arthritis and tolerability.
  • Examination of published guidelines for safe thalidomide use.

    • Main Results:

    • Thalidomide's efficacy is linked to TNF-alpha inhibition and integrin modulation.
    • The drug is used for erythema nodosum leprosum, GVHD, and severe ulcers in HIV/Behçet's disease.
    • Trials in rheumatoid arthritis were halted due to high adverse event rates, highlighting tolerability issues.

    Conclusions:

    • Thalidomide remains a valuable option for specific conditions unresponsive to standard therapies.
    • Strict adherence to safety guidelines, including monitoring nerve function and contraception, is crucial for safe use.
    • Ongoing research and careful patient selection are necessary to balance benefits and risks.